These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21926398)

  • 1. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
    Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
    Fornaro L; Crea F; Masi G; Paolicchi E; Loupakis F; Graziano F; Salvatore L; Ronzoni M; Ricci V; Cremolini C; Schirripa M; Danesi R; Falcone A
    Ann Oncol; 2012 May; 23(5):1370-1371. PubMed ID: 22383679
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
    BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
    Paolicchi E; Vivaldi C; De Gregorio V; Crea F; Fornaro L; Masi G; Loupakis F; Graziano F; Ronzoni M; Ricci V; Falcone A; Danesi R
    Oncology; 2016; 91(5):283-288. PubMed ID: 27577551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
    Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
    Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
    Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A
    Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
    Formica V; Cereda V; di Bari MG; Grenga I; Tesauro M; Raffaele P; Ferroni P; Guadagni F; Roselli M
    Med Oncol; 2013 Dec; 30(4):743. PubMed ID: 24114613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
    Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
    Suenaga M; Matsusaka S; Ueno M; Yamamoto N; Shinozaki E; Mizunuma N; Yamaguchi T; Hatake K
    Surg Today; 2011 Aug; 41(8):1067-74. PubMed ID: 21773895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.